MA45192A - Traitement d'association - Google Patents
Traitement d'associationInfo
- Publication number
- MA45192A MA45192A MA045192A MA45192A MA45192A MA 45192 A MA45192 A MA 45192A MA 045192 A MA045192 A MA 045192A MA 45192 A MA45192 A MA 45192A MA 45192 A MA45192 A MA 45192A
- Authority
- MA
- Morocco
- Prior art keywords
- association treatment
- association
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346854P | 2016-06-07 | 2016-06-07 | |
US201662432299P | 2016-12-09 | 2016-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45192A true MA45192A (fr) | 2019-04-10 |
Family
ID=60578133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045192A MA45192A (fr) | 2016-06-07 | 2017-06-06 | Traitement d'association |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200255524A1 (fr) |
EP (1) | EP3463464A4 (fr) |
JP (1) | JP2019517539A (fr) |
KR (1) | KR20190015520A (fr) |
CN (1) | CN109310762A (fr) |
AU (1) | AU2017278325A1 (fr) |
BR (1) | BR112018075198A2 (fr) |
IL (1) | IL263521A (fr) |
MA (1) | MA45192A (fr) |
MX (1) | MX2018014950A (fr) |
RU (1) | RU2018145961A (fr) |
SG (2) | SG10201913326UA (fr) |
TW (1) | TW201742636A (fr) |
WO (1) | WO2017214092A1 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
WO2014110601A1 (fr) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Nouvelles protéines hétérodimères |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
CR20160506A (es) | 2014-03-28 | 2017-03-10 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3 |
DK3223845T3 (da) | 2014-11-26 | 2021-08-16 | Xencor Inc | Heterodimere antistoffer, der binder cd3 og cd20 |
CA2968878A1 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps heterodimeriques se liant aux antigenes cd3 et cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3237449A2 (fr) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Anticorps trispécifiques |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
WO2017011580A2 (fr) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
EP3389714A4 (fr) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
WO2017218707A2 (fr) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Anticorps inhibiteurs de points de contrôle bispécifiques |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
EP3526241A1 (fr) | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Protéines de fusion fc hétérodimères il15/il15r |
CA3060618A1 (fr) | 2017-05-19 | 2018-11-22 | Wuxi Biologics (Shanghai) Co. Ltd. | Nouveaux anticorps monoclonaux diriges contre la proteine 4 associee aux lymphocytes t cytotoxiques (ctla-4) |
EP3630839A1 (fr) * | 2017-06-01 | 2020-04-08 | Xencor, Inc. | Anticorps bispécifiques liant cd123 cd3 |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
CA3071211A1 (fr) | 2017-08-04 | 2019-02-07 | Genmab A/S | Agents de liaison se liant a pd-l1 et cd137 et leur utilisation |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
CA3086199A1 (fr) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Proteines de fusion il-2 fc modifiees |
JP2021518748A (ja) * | 2018-02-23 | 2021-08-05 | アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc | カルシトニン遺伝子関連ペプチド(cgrp)アンタゴニスト抗体 |
EA202091982A1 (ru) * | 2018-03-14 | 2021-06-10 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
WO2019204655A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant tim-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de tim-3 |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
AU2019269383A1 (en) * | 2018-05-18 | 2020-12-10 | Duke University | Optimized GP41-binding molecules and uses thereof |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
JP2022513402A (ja) * | 2018-10-30 | 2022-02-07 | マクロジェニクス,インコーポレーテッド | 血液悪性腫瘍の治療のための二重特異性cd123×cd3ダイアボディ |
EP3930850A1 (fr) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Anticorps hétérodimères qui se lient à enpp3 et cd3 |
CN113727731B (zh) * | 2019-04-26 | 2023-06-02 | 上海药明生物技术有限公司 | 靶向pd-1和lag-3的双特异性抗体 |
CA3141531A1 (fr) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Polytherapies faisant appel a des inhibiteurs de cdk |
AU2020319875A1 (en) * | 2019-08-01 | 2022-02-17 | Incyte Corporation | A dosing regimen for an IDO inhibitor |
US20230056230A1 (en) * | 2019-12-23 | 2023-02-23 | Macrogenics, Inc. | Therapy for the Treatment of Cancer |
WO2021143826A1 (fr) * | 2020-01-17 | 2021-07-22 | 信达生物制药(苏州)有限公司 | Protéine de mort cellulaire 1 anti-programmée recombinante et préparation d'anticorps bispécifique anti-cluster d'antigène de différenciation 137 et son utilisation |
WO2021207770A1 (fr) * | 2020-04-11 | 2021-10-14 | Northwestern University | ANTICORPS HUMANISÉ CIBLANT L'ANTIGÈNE IL13Rα2 ASSOCIÉ À DES TUMEURS |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
CN112062859B (zh) * | 2020-07-24 | 2022-08-09 | 沣潮医药科技(上海)有限公司 | 用于病原体清除的嵌合抗原受体及其应用 |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
CN114437218B (zh) * | 2021-01-12 | 2022-09-30 | 北京门罗生物科技有限公司 | 靶向cd276的嵌合抗原受体以及包含其的免疫细胞 |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
WO2022192586A1 (fr) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
CN115611982A (zh) * | 2021-07-14 | 2023-01-17 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
WO2023001987A2 (fr) | 2021-07-22 | 2023-01-26 | University Of Dundee | Mutéines thérapeutiques |
WO2023057882A1 (fr) | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinaisons de composés d'azalactam avec un antagoniste de liaison à l'axe pd-1 pour le traitement du cancer |
WO2023079428A1 (fr) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Polythérapies utilisant un agoniste de tlr7/8 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2018248A1 (fr) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation |
US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US8414892B2 (en) | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
US7666424B2 (en) | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
PT1565489E (pt) | 2002-06-19 | 2011-02-23 | Raven Biotechnologies Inc | Anticorpos internalizantes específicos para o alvo de superfície celular raag10 |
SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
CN101687021B (zh) | 2007-03-22 | 2013-04-17 | 斯隆-凯特琳癌症研究院 | 单克隆抗体8h9的应用 |
US20100183615A1 (en) | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | IL13Ra2に対する抗体およびこれを含む診断・治療薬 |
EP2478110B1 (fr) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Anticorps anti-cea de classe i et leurs utilisations |
US8802091B2 (en) * | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
CA2802344C (fr) * | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques |
US20140170149A1 (en) * | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
WO2012147713A1 (fr) | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | Anticorps anti-b7-h3 |
MX347818B (es) | 2011-05-21 | 2017-05-15 | Macrogenics Inc | Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero. |
SI2714733T1 (sl) * | 2011-05-21 | 2019-06-28 | Macrogenics, Inc. | CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3 |
JP2014533929A (ja) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 5t4およびcd3に対する二重特異的結合性分子 |
PE20150891A1 (es) | 2012-11-07 | 2015-06-11 | Pfizer | Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco |
US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
EP2839842A1 (fr) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations |
RS60443B1 (sr) * | 2013-12-17 | 2020-07-31 | Genentech Inc | Anti-cd3 antitela i postupci upotrebe |
PT3083686T (pt) * | 2013-12-17 | 2019-12-18 | Hoffmann La Roche | Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos |
WO2015112534A2 (fr) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions et procédés pour moduler et réorienter des réponses immunitaires |
TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
PT3189081T (pt) | 2014-09-05 | 2020-05-25 | Janssen Pharmaceutica Nv | Agentes de ligação a cd123 e seus usos |
SG11201702544WA (en) * | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
DK3221355T3 (da) * | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN107614522A (zh) * | 2015-01-14 | 2018-01-19 | 指南针制药有限责任公司 | 多特异性免疫调节性抗原结合构建体 |
WO2017011413A1 (fr) | 2015-07-10 | 2017-01-19 | Duke University | Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1 |
WO2017011414A1 (fr) | 2015-07-10 | 2017-01-19 | Duke University | Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1 |
-
2017
- 2017-06-06 JP JP2018563801A patent/JP2019517539A/ja active Pending
- 2017-06-06 SG SG10201913326UA patent/SG10201913326UA/en unknown
- 2017-06-06 RU RU2018145961A patent/RU2018145961A/ru unknown
- 2017-06-06 CN CN201780035194.0A patent/CN109310762A/zh active Pending
- 2017-06-06 KR KR1020197000309A patent/KR20190015520A/ko not_active Application Discontinuation
- 2017-06-06 MA MA045192A patent/MA45192A/fr unknown
- 2017-06-06 SG SG11201810883TA patent/SG11201810883TA/en unknown
- 2017-06-06 BR BR112018075198-7A patent/BR112018075198A2/pt not_active IP Right Cessation
- 2017-06-06 MX MX2018014950A patent/MX2018014950A/es unknown
- 2017-06-06 US US16/306,882 patent/US20200255524A1/en not_active Abandoned
- 2017-06-06 WO PCT/US2017/036075 patent/WO2017214092A1/fr unknown
- 2017-06-06 AU AU2017278325A patent/AU2017278325A1/en not_active Abandoned
- 2017-06-06 EP EP17810823.9A patent/EP3463464A4/fr not_active Withdrawn
- 2017-06-07 TW TW106118940A patent/TW201742636A/zh unknown
-
2018
- 2018-12-05 IL IL263521A patent/IL263521A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112018075198A2 (pt) | 2019-03-19 |
CN109310762A (zh) | 2019-02-05 |
IL263521A (en) | 2019-01-31 |
TW201742636A (zh) | 2017-12-16 |
EP3463464A1 (fr) | 2019-04-10 |
KR20190015520A (ko) | 2019-02-13 |
RU2018145961A3 (fr) | 2020-07-30 |
JP2019517539A (ja) | 2019-06-24 |
RU2018145961A (ru) | 2020-07-14 |
WO2017214092A1 (fr) | 2017-12-14 |
SG11201810883TA (en) | 2019-01-30 |
AU2017278325A1 (en) | 2019-01-24 |
US20200255524A1 (en) | 2020-08-13 |
SG10201913326UA (en) | 2020-02-27 |
MX2018014950A (es) | 2019-04-25 |
EP3463464A4 (fr) | 2020-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45192A (fr) | Traitement d'association | |
DK3506854T3 (da) | Brystbehandlingsindretning | |
DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
MA45563A (fr) | Méthodes de traitement du cancer de l'ovaire | |
FR3036037B1 (fr) | Harnais d'encordement perfectionne | |
DK3474802T3 (da) | Medicinsk forbinding | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA47408A (fr) | Traitement du cancer | |
MA46062A (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
MA43106A (fr) | Traitement de l'oligo-ovulation associée à la stéatose hepatique | |
DK3408265T3 (da) | Terapeutiske forbindelser | |
DK3451886T3 (da) | Gulvbehandlingssystem | |
TWI800561B (zh) | 毛髮處理方法 | |
DK3580182T3 (da) | Vandbehandling | |
DK3407909T3 (da) | Cancerbehandling | |
MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
ES1109830Y (es) | " senalador de prendas" | |
UA37095S (uk) | Перев'язувальна пов'язка-бандаж | |
IT201700090331A1 (it) | "lopemide" | |
IT201700071679A1 (it) | Remembebe' | |
ITUA20163709A1 (it) | "presentosa3d" | |
UA32431S (uk) | Стрем'янка | |
UA33802S (uk) | Ванна «класіка» |